1. Articles in category: Burden of Treatment

    1-24 of 204 1 2 3 4 5 6 7 8 9 »
    1. Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

      Different infusion durations for preventing platinum-induced hearing loss in children with cancer.

      Cochrane Database Syst Rev. 2018 Jul 05;7:CD010885

      Authors: van As JW, van den Berg H, van Dalen EC

      Abstract BACKGROUND: Platinum-based therapy, including cisplatin, carboplatin or oxaliplatin, or a combination of these, is used to treat a variety of paediatric malignancies. Unfortunately, one of the most important adverse effects is the occurrence of hearing loss or ototoxicity.

      Read Full Article
      Mentions: Hearing Loss
    2. A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      A Comprehensive Safety Trial of Chimeric Antibody 14.18 With GM-CSF, IL-2, and Isotretinoin in High-Risk Neuroblastoma Patients Following Myeloablative Therapy: Children's Oncology Group Study ANBL0931.

      Front Immunol. 2018;9:1355

      Authors: Ozkaynak MF, Gilman AL, London WB, Naranjo A, Diccianni MB, Tenney SC, Smith M, Messer KS, Seeger R, Reynolds CP, Smith LM, Shulkin BL, Parisi M, Maris JM, Park JR, Sondel PM, Yu AL

      Read Full Article
      Mentions: Antibody COG
    3. Somatic late effects in 5-year survivors of neuroblastoma: A population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

      Somatic late effects in 5-year survivors of neuroblastoma: A population-based cohort study within the Adult Life after Childhood Cancer in Scandinavia (ALiCCS) study.

      Int J Cancer. 2018 Jun 21;:

      Authors: Norsker FN, Rechnitzer C, Cederkvist L, Tryggvadottir L, Madanat-Harjuoja LM, Øra I, Thorarinsdottir HK, Vettenranta K, Bautz A, Schrøder H, Hasle H, Winther JF

      Read Full Article
    4. Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

      Pediatric 131I-MIBG Therapy for Neuroblastoma: Whole-Body 131I-MIBG Clearance, Radiation Doses to Patients, Family Caregivers, Medical Staff, and Radiation Safety Measures.

      Clin Nucl Med. 2018 Jun 19;:

      Authors: Willegaignon J, Crema KP, Oliveira NC, Pelissoni RA, Coura-Filho GB, Sapienza MT, Buchpiguel CA

      Read Full Article
    5. Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

      Long-term psychological and educational outcomes for survivors of neuroblastoma: A report from the Childhood Cancer Survivor Study.

      Cancer. 2018 Jun 11;:

      Authors: Zheng DJ, Krull KR, Chen Y, Diller L, Yasui Y, Leisenring W, Brouwers P, Howell R, Lai JS, Balsamo L, Oeffinger KC, Robison LL, Armstrong GT, Kadan-Lottick NS

      Read Full Article
    6. Children with neuroblastoma have an elevated risk of long-term psychological difficulties

      A new study reveals that paediatric neuroblastoma patients are at elevated risk for long-term psychological impairment.

      In addition, those who experience such impairment as they get older tend to require special education services and to not go on to...

      Read Full Article
      Mentions: Treatment
    7. Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model

      Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model

      Cancer Therapy: Preclinical Enhanced Intratumoral Delivery of SN38 as a Tocopherol Oxyacetate Prodrug Using Nanoparticles in a Neuroblastoma Xenograft Model Ferro Nguyen , Ivan Alferiev , Peng Guan , David T. Guerrero , Venkatadri Kolla , Ganesh S. Moorthy , Michael Chorny and Garrett M. Brodeur Ferro Nguyen PDF Abstract Purpose: Currently, <50% of high-risk pediatric solid tumors like neuroblastoma can be cured, and many survivors experience serious or life-threatening toxicities, so more effective, less toxic therapy is needed. One approach is to target drugs to tumors using nanoparticles, which take advantage of the enhanced permeability of tumor vasculature. Experimental Design: SN38, the active metabolite of ...

      Read Full Article
      Mentions: Nanoparticles
    8. Both serum and tissue Galectin-1 levels are associated with adverse clinical features in neuroblastoma.

      Both serum and tissue Galectin-1 levels are associated with adverse clinical features in neuroblastoma.

      Pediatr Blood Cancer. 2018 May 24;:e27229

      Authors: Chen K, Cai Y, Zhang M, Wu Z, Wu Y

      Abstract BACKGROUND: Neuroblastoma is one of the most common pediatric solid tumors. Although the 5-year overall survival rate has increased over the past few decades, high-risk patients still have a poor prognosis due to a lack of biomonitoring therapy.

      Read Full Article
    9. Both serum and tissue Galectin‐1 levels are associated with adverse clinical features in neuroblastoma

      Neuroblastoma is one of the most common pediatric solid tumors. Although the 5‐year overall survival rate has increased over the past few decades, high‐risk patients still have a poor prognosis due to a lack of biomonitoring therapy. This study was performed to investigate the role of Galectin‐1 in neuroblastoma biomonitoring therapy. A tissue microarray containing 37 neuroblastoma tissue samples was used to evaluate the correlation between Galectin‐1 expression and clinical features.

      Read Full Article
    10. Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk MYCN-not-amplified Human Neuroblastoma.

      Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T Cell Receptors in High-risk MYCN-not-amplified Human Neuroblastoma.

      Clin Cancer Res. 2018 May 21;:

      Authors: Wei JS, Kuznetsov IB, Zhang S, Song YK, Asgharzadeh S, Sindiri S, Wen X, Patidar R, Nagaraj S, Walton A, Guidry Auvil JM, Gerhard DS, Yuksel A, Catchpoole DR, Hewitt SM, Sondel PM, Seeger RC, Maris JM, Khan J

      Read Full Article
      Mentions: MYCN
    11. Emerging role of immunotherapy for childhood cancers.

      Emerging role of immunotherapy for childhood cancers.

      Chin Clin Oncol. 2018 Apr;7(2):14

      Authors: Handgretinger R, Schlegel P

      Abstract Recent developments in cell and gene therapy have a great impact on the new therapeutic approaches in pediatric cancers. Monoclonal antibodies for neuroblastoma and bispecific antibodies for leukemia have induced significant clinical responses for otherwise chemorefractory patients.

      Read Full Article
      Mentions: Immunotherapy
    12. Evolving biopsy techniques for the diagnosis of neuroblastoma in children.

      Evolving biopsy techniques for the diagnosis of neuroblastoma in children.

      J Pediatr Surg. 2018 Apr 14;:

      Authors: Campagna G, Rosenfeld E, Foster J, Vasudevan S, Nuchtern J, Kim E, Commander S, Naik-Mathuria B

      Abstract BACKGROUND/PURPOSE: To compare the adequacy and safety of percutaneous core needle biopsy and surgical wedge biopsy of neuroblastoma in children.

      Read Full Article
      Mentions: Treatment Biopsy
    13. Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Strategies for enhancing adoptive T-cell immunotherapy against solid tumors using engineered cytokine signaling and other modalities.

      Expert Opin Biol Ther. 2018 May 04;:

      Authors: Shum T, Kruse RL, Rooney CM

      Abstract INTRODUCTION: Cancer therapy has been transformed by the demonstration that tumor-specific T-cells can eliminate tumor cells in a clinical setting with minimal long-term toxicity.

      Read Full Article
    14. Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Results of a phase II trial for high-risk neuroblastoma treatment protocol JN-H-07: a report from the Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG).

      Int J Clin Oncol. 2018 Apr 26;:

      Authors: Hishiki T, Matsumoto K, Ohira M, Kamijo T, Shichino H, Kuroda T, Yoneda A, Soejima T, Nakazawa A, Takimoto T, Yokota I, Teramukai S, Takahashi H, Fukushima T, Kaneko T, Hara J, Kaneko M, Ikeda H, Tajiri T, Nakagawara A, Japan Childhood Cancer Group Neuroblastoma Committee (JNBSG)

      Read Full Article
    15. BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma.

      BAP1 induces cell death via interaction with 14-3-3 in neuroblastoma.

      Cell Death Dis. 2018 Apr 24;9(5):458

      Authors: Sime W, Niu Q, Abassi Y, Masoumi KC, Zarrizi R, Køhler JB, Kjellström S, Lasorsa VA, Capasso M, Fu H, Massoumi R

      Abstract BRCA1-associated protein 1 (BAP1) is a nuclear deubiquitinating enzyme that is associated with multiprotein complexes that regulate key cellular pathways, including cell cycle, cellular differentiation, cell death, and the DNA damage response.

      Read Full Article
    16. Dehydroeffusol inhibits viability and epithelial-mesenchymal transition through the Hedgehog and Akt/mTOR signaling pathways in neuroblastoma cells.

      Dehydroeffusol inhibits viability and epithelial-mesenchymal transition through the Hedgehog and Akt/mTOR signaling pathways in neuroblastoma cells.

      Eur J Pharmacol. 2018 Apr 14;:

      Authors: He K, Duan G, Li Y

      Abstract Neuroblastoma (NB) is the most predominant extracranial solid tumor of infancy in the world. However, current chemotherapy has limited efficacy for more advanced stages of NB due to acquired chemoresistance or acute toxicity in NB patients.

      Read Full Article
      Mentions: Chemotherapy
    17. [Clinical features and prognosis of malignancy-associated hemophagocytic lymphohistiocytosis in children: a clinical analysis of 24 cases].

      [Clinical features and prognosis of malignancy-associated hemophagocytic lymphohistiocytosis in children: a clinical analysis of 24 cases].

      Zhongguo Dang Dai Er Ke Za Zhi. 2018 Apr;20(4):295-297

      Authors: Zhang WY, Zhang Y, Dong NN, Wang YC, Sheng GY, Xu XJ, Liu YF

      Read Full Article
    18. Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.

      Feasibility of Busulfan Melphalan and Stem Cell Rescue After 131I-MIBG and Topotecan Therapy for Refractory or Relapsed Metastatic Neuroblastoma: The French Experience.

      J Pediatr Hematol Oncol. 2018 Apr 10;:

      Authors: Ferry I, Kolesnikov-Gauthier H, Oudoux A, Cougnenc O, Schleiermacher G, Michon J, Bogart E, Chastagner P, Proust S, Valteau-Couanet D, Defachelles AS

      Read Full Article
    19. Acute toxicity of craniospinal irradiation with volumetric-modulated arc therapy in children with solid tumors.

      Acute toxicity of craniospinal irradiation with volumetric-modulated arc therapy in children with solid tumors.

      Pediatr Blood Cancer. 2018 Apr 06;:e27050

      Authors: Wong KK, Ragab O, Tran HN, Pham A, All S, Waxer J, Olch AJ

      Abstract BACKGROUND: Craniospinal irradiation (CSI) is an important part of curative radiation therapy (RT) for many types of pediatric brain or solid tumors. After conventional CSI, long term survivors may experience sequelae due to unintended dose to normal tissue.

      Read Full Article
    20. Acute toxicity of craniospinal irradiation with volumetric‐modulated arc therapy in children with solid tumors

      Craniospinal irradiation (CSI) is an important part of curative radiation therapy (RT) for many types of pediatric brain or solid tumors. After conventional CSI, long term survivors may experience sequelae due to unintended dose to normal tissue. Volumetric modulated arc therapy (VMAT) CSI reduces off‐target doses at the cost of greater complexity and error risk, and we describe our initial experience in a group of pediatric patients with solid tumors presenting with disseminated or recurrent disease. Pediatric patients with brain tumors were identified at Children's Hospital Los Angeles from 2013 to 2015. Clinical characteristics, acute toxicity, and radiotherapy ...

      Read Full Article
      Mentions: Radiotherapy
    21. Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

      Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial.

      Pediatr Blood Cancer. 2018 Mar 30;:e27023

      Authors: Pinto N, DuBois SG, Marachelian A, Diede SJ, Taraseviciute A, Glade Bender JL, Tsao-Wei D, Groshen SG, Reid JM, Haas-Kogan DA, Reynolds CP, Kang MH, Irwin MS, Macy ME, Villablanca JG, Matthay KK, Park JR

      Read Full Article
      Mentions: Refractory NANT
    1-24 of 204 1 2 3 4 5 6 7 8 9 »
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles